ESR1 and triple-negative breast carcinoma: MDA-MB-231 cell line was employed as a triple-negative breast cancer (TNBC) model, which has no targeted therapeutics because of triple negative expression in estrogen receptor (ER−), progesterone receptor (PR−) and HER2/neu (HER2−)21.